MetaSafe was initially founded in 2013 by ex Astra Zeneca biotransformation and ADME scientists at the time when AZ R&D in Södertälje was decommissioned. The aim was to maintain and develop biotransformation expertise and to make this long experience and expertise available to any pharma company. In 2018 MetaSafe became Admescope Sweden when aquired by Admescope (a Symeres company since 2020).
In 2022 MetaSafe was reborn in the transfer of Admescope’s Swedish operation to the CTR group in Sweden.
MetaSafe continues to provide expertise in metabolite analysis in the ADME field and particularly in the field of Metabolites in Safety testing and radiolabel-assisted metabolite analysis.
Still experts, still passionate!